STAT3 inhibition targets cytokine signaling and renal inflammation in systemic lupus erythematosus and lupus nephritis
New review suggests STAT3 inhibition could help lupus kidney disease
This narrative review examines the role of STAT3 in systemic lupus erythematosus and lupus nephritis. The authors argue that STAT3 integrate…
A narrative review suggests targeting STAT3 might treat lupus kidney inflammation, though direct drug targeting remains unproven in patients…
Tubulointerstitial inflammation and fibrosis predict renal function decline in adult lupus nephritis patients across multiple studies
Kidney damage in lupus is linked to specific tissue changes seen in scans
A systematic review of 3,607 adult patients reveals that tubulointerstitial inflammation and fibrosis significantly increase the risk of ren…
A large review found that kidney tissue changes called tubulointerstitial inflammation and fibrosis raise the risk of kidney failure in lupu…
Commentary on plateau in lupus nephritis trials and path to precision medicine
New lupus drugs hit a ceiling where kidney healing stops improving
This commentary reviews 200 interventional pharmacological trials in lupus nephritis. The authors note a persistent ceiling effect with comp…
Kidney healing in lupus patients using new drugs often stops improving after reaching a 40 to 50 percent success rate, limiting how much bet…
Meta-analysis of belimumab versus anifrolumab in systemic lupus erythematosus and lupus nephritis
Belimumab and anifrolumab show different strengths for lupus patients
This meta-analysis compared belimumab and anifrolumab using indirect evidence from randomized controlled trials involving 4332 patients with…
A new analysis compares two lupus drugs. Belimumab worked better for overall disease control, while anifrolumab helped lower steroid doses a…
Meta-analysis links CYP2C19*2 polymorphism to reduced cyclophosphamide toxicity in SLE
Genetic marker may lower risk of cyclophosphamide toxicity in lupus patients
This meta-analysis of 5 observational studies found that the CYP2C19*2 genetic polymorphism is associated with a protective effect against…
A genetic variant linked to lower risk of cyclophosphamide side effects in lupus patients, though evidence remains limited by small study si…
Systematic Review Links Lysosomal Pathways to Autoimmune Kidney Disease Progression
Lysosomal pathways may control autoimmune kidney disease progression
This systematic review synthesizes evidence that lysosomal functions act as checkpoints in autoimmune kidney diseases like lupus nephritis a…
New evidence suggests that targeting lysosomal functions could offer a new way to manage serious autoimmune kidney diseases.
Mini Review Covers Complement Pathways in Kidney Diseases and Injuries
Review offers overview of kidney disease treatments and risks
This mini review examines the role of complement-mediated mechanisms across multiple renal pathologies without specific outcome data.
This mini review summarizes current knowledge on kidney conditions like lupus nephritis and transplant care, offering a broad look at the fi…
Rituximab pharmacokinetics vary widely in membranous nephropathy, minimal change disease, and lupus nephritis patients
Rituximab Works — But Only If Your Body Keeps Enough of It
This review examined pharmacokinetic profiling of rituximab in patients with glomerular diseases.
Rituximab helps kidney disease patients only if their bodies keep enough of it in the blood, since some people clear the drug too fast and g…
Retrospective Analysis of Repeat Kidney Biopsy Outcomes in 19 Pediatric Lupus Nephritis Patients
Small study examines repeat kidney biopsies in children with lupus nephritis
This retrospective cohort study evaluated 19 pediatric lupus nephritis patients aged 5 to 18 years at Nanjing Children's Hospital between 20…
A small study of 19 children with lupus nephritis shows how repeat kidney biopsies track disease changes over time to guide future treatment…
LOC100130476 rs80213143 variant associated with SLE susceptibility and renal involvement in Chinese Han cohort
Genetic variant linked to lupus susceptibility and kidney involvement in Chinese study
A cohort study in a Chinese Han population found the rs80213143 variant at LOC100130476 was associated with systemic lupus erythematosus sus…
A specific genetic marker found in Chinese patients is strongly linked to lupus and predicts more severe kidney disease.
Review examines glucose metabolic reprogramming in SLE and lupus nephritis pathogenesis
Review explores how sugar metabolism changes might fuel lupus immune system problems
A systematic review synthesizes evidence on glucose metabolic reprogramming in immune cells in systemic lupus erythematosus and lupus nephri…
Lupus immune cells change how they use sugar for energy, a shift that drives the disease and kidney damage, opening doors to new metabolic t…
Phase 3 Trial of Cenerimod for Lupus Nephritis: Efficacy and Safety Evaluation
Could a New Drug Help Improve Kidney Function in Lupus Patients?
A Phase 3 trial is assessing cenerimod's efficacy and safety in treating active lupus nephritis. The primary endpoint is complete renal resp…
A new trial tests whether adding cenerimod to regular treatment can improve kidney function in adults with active lupus nephritis over 76 we…
Research across Systemic Lupus Erythematosus
Related studies from across the Systemic Lupus Erythematosus family.
Dapirolizumab pegol increases BICLA response rate by 14.6% over placebo in moderate-to-severe SLE
Trial shows dapirolizumab pegol improves symptoms for lupus patients
This Phase 3 randomized controlled trial of 321 patients with moderate-to-severe, active SLE found that dapirolizumab pegol added to standar…
A new clinical trial found that dapirolizumab pegol significantly improved disease activity for adults with moderate to severe systemic lupu…
SLE patients have a 2- to 3-fold higher risk of intracerebral hemorrhage compared to non-SLE populations
Lupus Patients Face Higher Risk of Brain Bleeding
This literature review and case report analyze the association between systemic lupus erythematosus (SLE) and intracranial hemorrhage (ICH).…
Patients with systemic lupus erythematosus may face a much higher risk of brain bleeds compared to those without the condition.
Systemic immune-inflammation index and systemic inflammation response index correlate with disease activity in systemic lupus erythematosus
Inflammation markers are higher in lupus patients than in healthy people
This meta-analysis of eleven studies involving individuals with systemic lupus erythematosus and healthy controls examined inflammatory mark…
A new analysis shows inflammation markers are much higher in people with lupus. These markers also track closely with how active the disease…
Stress-induced IL-6 upregulation impairs skeletal growth and bone health in children with inflammatory diseases
Stress hormones may harm bone growth in children with inflammatory conditions
This narrative review synthesizes evidence from animal models and pediatric inflammatory disorders showing that stress-induced IL-6 upregula…
A review suggests stress-induced IL-6 upregulation impairs skeletal growth and bone health in kids with inflammatory disorders, highlighting…
Adrenal insufficiency is first manifestation in 73.6% of APS patients with adrenal involvement
Review finds adrenal crisis common in lupus and antiphospholipid syndrome cases
This systematic review and pooled individual-patient analysis of 155 published APS/SLE-spectrum patients with adrenal involvement found that…
A review of 155 patients shows adrenal crisis is frequent in lupus and antiphospholipid syndrome, highlighting the need for urgent care.
SLE linked to 53% higher odds of cognitive impairment in meta-analysis of 7 million
Lupus linked to higher risk of cognitive decline
This meta-analysis of 7 observational studies involving over 7 million participants found that systemic lupus erythematosus (SLE) is signifi…
People with lupus may face 53% higher odds of cognitive impairment, a large analysis finds.
Epstein–Barr virus infection shows higher seropositivity and viral loads in systemic lupus erythematosus patients compared to healthy controls
Epstein-Barr virus linked to lupus in new review of patient data
A mini review highlights that Epstein–Barr virus infection is more prevalent and active in patients with systemic lupus erythematosus than i…
A new review finds that Epstein-Barr virus is more common and active in lupus patients, suggesting a role in the disease.
Subcutaneous anifrolumab improves BICLA response by 15.5% in moderate to severe SLE
Anifrolumab injection improves lupus outcomes in trial
This phase 3 RCT in 367 adults with moderate to severe SLE found that subcutaneous anifrolumab 120 mg weekly plus standard therapy improved …
A weekly injection of anifrolumab helped more people with lupus achieve disease control than placebo, a phase 3 trial shows.
Core set domains capture SLE treatment response in 89.5% of cases at week 52
Core set domains capture most lupus disease activity in a global trial
This phase III randomized controlled trial evaluated subjects with Systemic Lupus Erythematosus across a global setting. The study compared …
A global trial found that a core set of domains captured most lupus disease activity without missing important patient responses.
Meta-analysis finds hydroxychloroquine does not reduce most pregnancy complications in SLE
Hydroxychloroquine May Lower Risk of Fetal Growth Restriction in Lupus Pregnancy
This meta-analysis of observational studies and RCTs assessed hydroxychloroquine use in pregnant women with SLE. It found no significant red…
In lupus pregnancies, hydroxychloroquine was linked to lower risks of fetal growth restriction and gestational diabetes, but not other compl…
Meta-analysis finds systemic lupus erythematosus elevates coronary artery disease risk
People with lupus face higher heart disease risk but genetics show no direct link
This meta-analysis of 2,517,781 individuals from European and East Asian populations found that systemic lupus erythematosus is associated w…
A massive analysis of millions of people found those with lupus have a much higher risk of heart disease, though genetics do not prove a dir…
Narrative review discusses CD40/CD40L signaling regulation in rheumatoid arthritis and other autoimmune conditions
Safer CD40/CD40L targeting needs selectivity for autoimmune diseases
This narrative review examines CD40/CD40L signaling regulation in rheumatoid arthritis, systemic lupus erythematosus, and Sjogren's syndrome…
A narrative review suggests that safer therapeutic targeting of CD40/CD40L signaling will require greater selectivity to treat rheumatoid ar…
Questions about Lupus Nephritis
Do complement pathways cause kidney injuries in patients with lupus nephritis?
Yes, complement pathways — especially the classical and alternative pathways — contribute to kidney injury in lupus nephritis by driving inflammation and tissue damage after immune complex deposition.
Full answer →Is there a genetic variant linked to lupus nephritis risk in Chinese Han populations?
Yes, the rs80213143 variant in LOC100130476 is linked to lupus nephritis risk in Chinese Han populations, with the C allele associated with more severe kidney involvement.
Full answer →What role do lysosomal pathways play in the progression of autoimmune kidney disease like lupus nephritis?
Lysosomal pathways act as checkpoints that regulate immune activation, autoantigen processing, and metabolic-immune crosstalk, driving lupus nephritis progression.
Full answer →Does having the CYP2C19*2 gene variant protect against cyclophosphamide side effects in lupus nephritis?
Yes, the CYP2C19*2 variant is linked to reduced cyclophosphamide toxicity in lupus nephritis, based on a meta-analysis showing a protective effect.
Full answer →How does belimumab compare to anifrolumab for treating lupus nephritis?
Belimumab is approved for lupus nephritis and appears more effective than anifrolumab, which is not yet approved for this condition.
Full answer →